Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- MHLW Sends FPMAJ Details of New Point-Based Calculations for New Drug Pricing
May 14, 2014
- PIC/S to Discuss Japan’s Accession at Upcoming Meeting in Rome; MHLW Anticipates Formal Approval
May 14, 2014
- PMDA Raises Caution about Concomitant Use of ACE Inhibitors and ARBs
May 13, 2014
- Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
- Joint Panel of Health, Science Ministries Wraps Up Talks on Ethics Code for Epidemiological, Clinical Research
May 2, 2014
- Topical Ketoprofen Contraindicated in Later Pregnancy: MHLW Safety Information
May 2, 2014
- Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
- PAFSC’s Second Committee Backs Approval of Janssen, Sanofi Prostate Cancer Drugs
May 1, 2014
- PAFSC’s First Committee Recommends Approval for SGLT-2 Inhibitor Canaglu
April 30, 2014
- Kitasato Daiichi to Carry on with Delayed Quota in Flu Vaccine Project, but Slapped with Delinquency Charges
April 30, 2014
- Kaketsuken, Takeda Picked for Flu Vaccine Project to Fill BIKEN Quota
April 30, 2014
- MHLW Issues Notification Calling for Revision of Package Insert for Sanofi’s Benambax
April 30, 2014
- MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
- MHLW Should Present Its Own Proposal to Design Envisioned Mixed Care System: Panel Chair
April 28, 2014
- PMDA’s Preliminary Meetings, Face-to-Face Counseling Rise in FY2013
April 28, 2014
- Chuikyo Healthcare Provider Rep Vexed by Health Minister Proposal on Use of Drug Cost-Effective Assessment
April 25, 2014
- JMA Veep Nakagawa Fumes at Industry, Says “Application Lag” Elicited New Mixed Care Proposal
April 25, 2014
- Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
- LDP Study Group to Call for Expansion of R&D Tax Credit System, Oppose Annual NHI Price Cuts
April 24, 2014
- PAFSC’s Second Committee to Discuss Janssen, Sanofi Prostate Cancer Drugs on April 30
April 23, 2014
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…